Metformin is the most widely used oral
antihyperglycemic agent for the improvement of type 2 diabetes mellitus (T2DM).
In patients with T2DM, metformin increases insulin
sensitivity and reduces glucose production. In this systematic review, we
identified and compared metabolic changes induced by metformin administration.
We searched articles published within the past
5 years on Pubmed.gov by using the keywords “metformin and metabolomics.” No
restrictions were placed on the languages, species, or gender during the
selection of articles.
From the 29 identified articles, we excluded
non-human in vivo or in vitro studies, studies in cancer patients, and studies
in which the focus was not on variation in the levels of metabolites after
administration of medication such as pharmacogenetic studies. Finally, we
selected 8 articles and compared their results.
No comments:
Post a Comment